Debiopharm Group? Moves Forward Three of Its Oncology Clinical Programs and Will Present the Recent Progresses at the 50th American Society of Clinical Oncology (ASCO) Annual Meeting - Applied

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Debiopharm Group? Moves Forward Three of Its Oncology Clinical Programs and Will Present the Recent Progresses at the 50th American Society of Clinical Oncology (ASCO) Annual Meeting


Debiopharm Group™ Moves Forward Three of Its Oncology Clinical Programs and Will Present the Recent Progresses at the 50th American Society of Clinical Oncology (ASCO) Annual Meeting

PR Newswire

LAUSANNE, Switzerland, May 28, 2014 /PRNewswire/ --

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, today announced that new data on the investigational compounds Debio 1143 (SMAC mimetic), Debio 1347/CH5183284 (FGFR 1,2,3 inhibitor), and Debio 0932 (Hsp90 inhibitor) will be presented at the 50th American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 to June 3, 2014, in Chicago.

Debio 1143 is an orally available small molecule inhibitor of apoptosis proteins (IAPs) that mimics the activity of the natural second mitochondrial-derived activator of caspases (SMAC). By targeting IAPs, Debio 1143 can induce cancer cell death and potentiate the efficacy of chemo- and/or radiotherapy. Debio 1143 has been assessed in two phase I clinical studies and two phase I/II trials are ongoing in Europe.

Debio 1347/CH5183284 is a selective oral fibroblast growth factor receptor (FGFR) 1, 2, 3 inhibitor that has shown anti-cancer efficacy in several preclinical animal models in vivo. Debio 1347/CH5183284 will enable personalized treatments and will be developed with a companion diagnostic. Debio 1347/CH5183284 is currently being evaluated in Europe and USA, in a first-in-man phase I trial in patients with advanced solid tumors displaying alterations of the FGFR 1, 2, or 3 genes.

Debio 0932 is a small oral molecule inhibitor of heat shock protein 90 (HSP90). Inhibition of HSP90 results in the degradation of oncoproteins that drive malignant progression and leads to cell death. Debio 0932 has shown efficacy in various mouse tumor xenografts and exhibits sustained tumor retention. Debio 0932 has been investigated in one phase I clinical study. Two phase I/II studies are ongoing in Europe in advanced non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC) in combination with SOC and everolimus, respectively.

"We are very pleased to present results of our strong involvement in cancer treatment research and further establish our commitment to this challenging medical field," said Jean-Maurice Dumont, Vice-President Medical Affairs. "The ability to relieve people with cancer is an accomplishment."

List of abstracts presented at ASCO:

               
               Abstract & Poster
               Compound   Description of study                                            number
               Debio 1143 First-in-human, pharmacokinetic (PK) and pharmacodynamics        #2532
               (PD) phase I study of Debio 1143 (AT406) in patients with
               advanced cancer. Final results.
               Phase I study of Debio 1143 (AT406) in combination with          #7029
               daunorubicin (D) and cytarabine (C) in patients with
               poor-risk acute myeloid leukemia (AML).
               A phase I/II randomized study of Debio 1143 combined with      #TPS6097
               concurrent chemo-radiation therapy (CCRT) in patients with
               locally advanced squamous cell carcinoma of the head and
               neck (LA-SCCHN).
               Clinical PK/PD model for Debio 1143, a novel antagonist of       #2585
               IAPs in cancer treatment
               
               Debio 1347 First-in-human phase I "basket" study of Debio1347             #TPS2629
               (CH5183284), a novel FGFR inhibitor, in patients with FGFR
               genomically activated advanced solid tumors.
               
               Debio 0932 Final results from the phase I study expansion cohort of         #2550
               Debio 0932, an oral HSP90 inhibitor, in patients with
               solid tumors.
               The HALO study: A phase I-II of the oral HSP90 inhibitor       #TPS2632
               Debio 0932 in combination with SOC in first- and
               second-line therapy of advanced NSCLC.
               

About Debiopharm Group

Debiopharm Group™ is a Swiss-based global biopharmaceutical group of four companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investments. Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses, develops and/or co-develops promising biological and small molecule drug candidates for global registration. The products are commercialized through out-licensing to pharmaceutical partners to give access to the largest number of patients worldwide.

For more information about Debiopharm Group™, please visit: http://www.debiopharm.com.

Debiopharm International SA Contact
Christelle Tur
Communication Coordinator
christelle.tur@debiopharm.com
Tel.: +41(0)21-321-01-11

Additional Media Contacts
In London
Maitland
Brian Hudspith
bhudspith@maitland.co.uk
Tel: +44(0)20-7379-5151

In New York
Russo Partners, LLC
Martina Schwarzkopf, Ph.D.
Account Executive
martina.schwarzkopf@russopartnersllc.com
Tel: +1-212-845-4292

SOURCE Debiopharm Group

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here